News

Second Lorcaserin Review to Address Risk/Benefit Tradeoffs

Publish date: March 21, 2012

 

A decision is expected in late June.

Emily Hayes is with "The Pink Sheet." This news organization and "The Pink Sheet" are owned by Elsevier.

Pages

Recommended Reading

PCI Trial Halted After FFR's Benefit Shown
MDedge Cardiology
Risk Factors, Not Race, Determine Lifetime Heart Risks
MDedge Cardiology
Experts Can't Pin Down Best Carotid Atherosclerosis Treatments
MDedge Cardiology
Vytorin Falls Short of New Indication for CKD Patients
MDedge Cardiology
Updated Criteria Revisit PCI Appropriateness Scenarios
MDedge Cardiology
Her Chief Complaint Is ... And by the Way She’s Also Pregnant
MDedge Cardiology
Stents Don't Surpass Pills in Stable CAD
MDedge Cardiology
Desensitization Succeeds for Aspirin-Allergic Heart Patients
MDedge Cardiology
Slight Hyperglycemia Risk Shouldn't Deter Statin Use
MDedge Cardiology
Arthritis Plus Hypothyroidism Ups Women's CVD Risk
MDedge Cardiology